ghk cu iniekcja GHK-CU GHK-Cu 100 mg – Peptyd

A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007

Almeida L, Nunes T, Costa R, Rocha JF, Vaz-da-Silva M, Soares-da-Silva P

The research is young but growing rapidly, and BPC-157 stands out as a compound with profound regenerative potential

In addition to nausea, some individuals may also experience a sensation of bloating or gas, which can accompany the upset stomach

Its important that BPC-157 therapy be closely supervised by a medical professional

While human data is less robust, this dual-action potential (reducing existing fat while potentially limiting new accumulation) positions AOD-9604 as a promising component for long-term weight maintenance strategies